ATE290531T1 - Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten - Google Patents

Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten

Info

Publication number
ATE290531T1
ATE290531T1 AT02002073T AT02002073T ATE290531T1 AT E290531 T1 ATE290531 T1 AT E290531T1 AT 02002073 T AT02002073 T AT 02002073T AT 02002073 T AT02002073 T AT 02002073T AT E290531 T1 ATE290531 T1 AT E290531T1
Authority
AT
Austria
Prior art keywords
hyperplasia
pyran
onenes
dihydropyran
diseases
Prior art date
Application number
AT02002073T
Other languages
English (en)
Inventor
Suvit Thaisrivongs
Chih-Ping Yang
Joseph Walter Strohbach
Stephen Ronald Turner
Donna Lee Romero
Louis L Skaletzki
Paul Adrian Aristoff
Ronald B Gammill
Paul D Johnson
Harvey Irving Skulnick
Richard C Piper
Ruben A Tommasi
Qingwei Zhang
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE290531T1 publication Critical patent/ATE290531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT02002073T 1992-11-13 1993-11-09 Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten ATE290531T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US9087693A 1993-07-13 1993-07-13
US13064193A 1993-10-01 1993-10-01

Publications (1)

Publication Number Publication Date
ATE290531T1 true ATE290531T1 (de) 2005-03-15

Family

ID=27376682

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94900546T ATE223910T1 (de) 1992-11-13 1993-11-09 Pyran-2-onen und 5,6-dihydropyran-2-onen verwendbar für die behandlung von hiv und anderen tetroviren
AT02002073T ATE290531T1 (de) 1992-11-13 1993-11-09 Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94900546T ATE223910T1 (de) 1992-11-13 1993-11-09 Pyran-2-onen und 5,6-dihydropyran-2-onen verwendbar für die behandlung von hiv und anderen tetroviren

Country Status (26)

Country Link
EP (2) EP1203770B1 (de)
JP (1) JP3583127B2 (de)
KR (1) KR100314975B1 (de)
CN (1) CN1040321C (de)
AT (2) ATE223910T1 (de)
AU (1) AU687368B2 (de)
BR (1) BR9307451A (de)
CA (1) CA2145661C (de)
CZ (1) CZ291853B6 (de)
DE (2) DE69332292T2 (de)
DK (2) DK1203770T3 (de)
ES (2) ES2237624T3 (de)
FI (1) FI120399B (de)
GE (1) GEP20094660B (de)
HU (1) HU228126B1 (de)
IL (1) IL107556A (de)
LV (1) LV13088B (de)
MY (1) MY119031A (de)
NO (1) NO319914B1 (de)
NZ (1) NZ258013A (de)
PL (1) PL178653B1 (de)
PT (2) PT1203770E (de)
RU (1) RU2134691C1 (de)
SK (1) SK285001B6 (de)
WO (1) WO1994011361A1 (de)
ZA (1) ZA938019B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7636894A (en) * 1993-09-17 1995-04-03 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
EE9600044A (et) * 1993-11-19 1996-10-15 Parke, Davis & Company Püranooni derivaadid kui proteaasi inhibiitorid ja viirusevastased toimeained
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
DE69432056T2 (de) * 1993-11-19 2003-10-09 Parke Davis & Co Pyron derivate als protease inhibitoren und antivirusmitteln
CA2176043A1 (en) * 1993-11-19 1995-05-26 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2160733C2 (ru) * 1993-11-19 2000-12-20 Парк, Дэвис энд Компани Производные пирона и их фармацевтически приемлемые соли, промежуточные соединения для их получения, фармацевтическая композиция с антивирусной и антибактериальной активностью на их основе, способ лечения вызванных ретровирусом инфекции или заболевания
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EP0817786B1 (de) * 1995-03-20 2003-02-19 PHARMACIA & UPJOHN COMPANY Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
KR100569771B1 (ko) * 1997-09-11 2006-04-11 파마시아 앤드 업존 캄파니 엘엘씨 프로테아제 억제제로서 유용한 4-히드록시-2-옥소-피란유도체의 제조 방법
AU756965B2 (en) 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
EP1281399A3 (de) * 2001-08-01 2004-02-11 Warner-Lambert Company Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
JP4638441B2 (ja) 2003-10-24 2011-02-23 ロンザ アーゲー ６，６，６−トリハロ−３，５−ジオキソヘキサン酸エステルの生産方法
NZ573706A (en) * 2006-06-16 2011-09-30 Pharma Mar Sa Antitumoral dihydropyran-2-one compounds
DK2231590T3 (da) 2007-12-20 2012-07-09 Pharma Mar Sa Antitumorforbindelser
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
EP2346885B1 (de) 2008-11-05 2013-08-28 Clariant International Ltd. Verfahren zur herstellung von monocarboxyfunktionaslisierten dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
WO2010051893A1 (de) 2008-11-07 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
CN102171226B (zh) 2008-11-11 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙基化合物制备单烯丙基官能化的二烷基次膦酸、其盐或酯的方法以及它们的用途
DE102008060036A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
EP2379573B1 (de) 2008-12-18 2013-12-11 Clariant Finance (BVI) Limited Verfahren zur herstellung von ethylendialkylphosphinsäuren, -estern und -salzen mittels acetylen und ihre verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
CN114835694A (zh) * 2022-05-25 2022-08-02 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
AU4074789A (en) * 1988-03-01 1989-09-22 Upjohn Company, The Coumarins to inhibit reverse transcriptase in humans

Also Published As

Publication number Publication date
CN1040321C (zh) 1998-10-21
NZ258013A (en) 1997-02-24
MY119031A (en) 2005-03-31
PL308998A1 (en) 1995-09-18
KR100314975B1 (ko) 2002-02-28
DE69333771T2 (de) 2006-04-06
DE69332292T2 (de) 2003-05-28
NO319914B1 (no) 2005-10-03
ES2182837T3 (es) 2003-03-16
GEP20094660B (en) 2009-03-25
ES2237624T3 (es) 2005-08-01
DE69333771D1 (de) 2005-04-14
RU95112465A (ru) 1997-03-20
SK285001B6 (sk) 2006-04-06
DE69332292D1 (de) 2002-10-17
CZ107895A3 (en) 1995-12-13
HU9501411D0 (en) 1995-06-28
DK1203770T3 (da) 2005-05-23
AU5549394A (en) 1994-06-08
HU228126B1 (en) 2012-12-28
JP3583127B2 (ja) 2004-10-27
PT668860E (pt) 2003-01-31
FI952302A (fi) 1995-05-11
SK61695A3 (en) 1995-10-11
IL107556A (en) 2001-08-08
EP1203770B1 (de) 2005-03-09
ZA938019B (en) 1995-04-28
EP0668860B1 (de) 2002-09-11
CN1090279A (zh) 1994-08-03
CA2145661A1 (en) 1994-05-26
NO951899L (no) 1995-07-12
KR950704290A (ko) 1995-11-17
FI952302A0 (fi) 1995-05-11
HUT71558A (en) 1995-12-28
LV13088B (en) 2004-01-20
CA2145661C (en) 2008-04-01
PL178653B1 (pl) 2000-05-31
CZ291853B6 (cs) 2003-06-18
AU687368B2 (en) 1998-02-26
EP0668860A1 (de) 1995-08-30
JPH08503216A (ja) 1996-04-09
EP1203770A1 (de) 2002-05-08
DK0668860T3 (da) 2003-01-20
WO1994011361A1 (en) 1994-05-26
RU2134691C1 (ru) 1999-08-20
ATE223910T1 (de) 2002-09-15
NO951899D0 (no) 1995-05-12
PT1203770E (pt) 2005-05-31
BR9307451A (pt) 1999-08-31
IL107556A0 (en) 1994-02-27
FI120399B (fi) 2009-10-15

Similar Documents

Publication Publication Date Title
ATE290531T1 (de) Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die behandlung von hyperplasie und andere krankheiten
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
MY138240A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
TW270922B (de)
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
DE69125714T2 (de) Zusammensetzung für die behandlung des humanen prostata adenokarzinom
MXPA99002296A (es) Metodo para tratar alopecia androgenica con inhibidores de reductasa 5-alfa.
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
BR9203266A (pt) Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
ATE241359T1 (de) Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
ITMI922801A0 (it) Antiandroigeni per la terapia dell'ipertrofia prostatica dell'irsutismo dell'acne e della seborrea e relativi procedimenti di preparazione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1203770

Country of ref document: EP